TD Asset Management Inc Increases Stake in Insulet Corporation $PODD

TD Asset Management Inc grew its position in shares of Insulet Corporation (NASDAQ:PODD) by 11.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,119 shares of the medical instruments supplier’s stock after buying an additional 4,551 shares during the quarter. TD Asset Management Inc owned 0.06% of Insulet worth $12,540,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of PODD. NewEdge Advisors LLC increased its holdings in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares in the last quarter. Cresset Asset Management LLC increased its holdings in shares of Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares in the last quarter. Cerity Partners LLC increased its holdings in shares of Insulet by 68.7% in the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Insulet by 27.4% in the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after purchasing an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its holdings in shares of Insulet by 2.5% in the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after purchasing an additional 791 shares in the last quarter.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PODD. Citigroup cut their price target on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. Leerink Partners cut their price target on shares of Insulet from $360.00 to $247.00 in a report on Thursday, May 7th. Rothschild & Co Redburn reiterated a “neutral” rating and issued a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Benchmark reiterated a “buy” rating on shares of Insulet in a report on Wednesday, May 27th. Finally, Sanford C. Bernstein cut their price target on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $250.00.

Insulet Stock Performance

NASDAQ:PODD opened at $151.51 on Tuesday. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $174.40 and a two-hundred day moving average price of $236.99. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The company has a market capitalization of $10.49 billion, a P/E ratio of 35.23, a price-to-earnings-growth ratio of 1.21 and a beta of 1.13.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period last year, the firm posted $1.02 EPS. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.